Summit Therapeutics Inc. Contract Liability (Deferred Revenue)
Summit Therapeutics Inc. (SMMT) had Contract Liability (Deferred Revenue) of $0 as of 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-11-07
- 2023-09-30: Contract with Customer, Liability, Current $0.00.
- 2023-06-30: Contract with Customer, Liability, Current $0.00.
- 2023-03-31: Contract with Customer, Liability, Current $0.00.
- 2022-12-31: Contract with Customer, Liability, Current $0.00.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-07 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 |
| 2022-06-30 | $3.23M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $5.10M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $7.94M 10-Q · filed 2023-11-07 |
| 2021-09-30 | $7.51M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $7.14M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $7.42M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $8.37M 10-K · filed 2023-03-09 |
| 2020-09-30 | $7.11M 10-Q · filed 2020-11-16 |
| 2019-12-31 | $2.62M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |